Navigation Links
ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
Date:8/9/2012

e taxes and items that are not deductible for tax purposes such as stock compensation, increases in the fair value of contingent consideration and certain amortization, also increase our effective tax rate.  We expect our effective tax rate to decline in future years as profits increase, especially if those profits are attributable to our foreign operations.

Working Capital HighlightsAt June 30, 2012, our working capital was $424.8 million compared to $537.3 million at December 31, 2011.  Operating cash flow was $74.9 million in the first six months of 2012 compared to $68.5 million during the first six months of 2011.

Looking ahead ViroPharma is adjusting each of the elements of its guidance for the year 2012.  The following guidance and peak year sales estimates provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2012, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $450 to $475 million, reflective of updated expectations for Vancocin;
  • Net U.S. Cinryze sales are expected to be $320 to $335 million; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $215 to $235 million.

    • In addition, ViroPharma expects the following:

  • HAE/IV-only North American and European peak year Cinryze net product sales are expected to exceed $700 million driven by increased expectations in North America; and
  • European peak year net product sales are expected to be between $300 to $500 million.

    • Non-GAAP DisclosuresThe Company is reporting both GAAP net income (loss) and non-GAAP adjusted results for the three and six month periods ended June 30,
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
    2. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
    3. ViroPharma To Participate In The JMP Securities Healthcare Conference
    4. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
    7. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
    8. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
    9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
    10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
    11. GenVec Reports Second Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
    (Date:5/19/2013)... 20, 2013 Claret Medical, Inc. announced the publication ... Mieghem et al., Histopathology of Embolic Debris ... print in Circulation, May 7 th this research is ... Rotterdam, the Netherlands and the pathology team ... Cardiovascular Pathology Institute, Gaithersburg, Maryland.  This is ...
    (Date:5/18/2013)... , May 18, 2013 Faruqi & ... is investigating potential securities fraud at AVEO Pharmaceuticals, ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by issuing ... Phase III drug trials for Tivopath (tivozanib) (titled ...
    Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
    ... N.J., May 14, 2012  MAQUET Cardiovascular LLC, a leading ... received 510(k) clearance from the U.S. Food and Drug ... 40cc intra-aortic balloon (IAB) catheters. These new, larger volume ... hemodynamic support, regardless of their height.  ...
    ... The increasing incidence of thrombosis, paralleled by ... motivating the need for novel alternatives. Establishing end-user ... market advancement. However, the launch of three blockbuster ... therapeutics market address these challenges. It is also ...
    Cached Medicine Technology:MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes 2MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes 3European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan 2European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan 3
    (Date:5/20/2013)... 20, 2013 Sporturf, an international manufacturer ... its presence in the Midwest with the opening of ... Missouri. Sporturf Midwest is under the leadership of ... Missouri and Kansas. , “This strategic move ... been in before,” noted Shonk. “Bringing an ISO manufacturer ...
    (Date:5/20/2013)... Online education provides the convenience, ... does not offer. According to the American Heart ... switching classroom learning to eLearning due to changing ... helped maximize training budgets, but it is also ... by 25–60%. A higher retention of content is ...
    (Date:5/20/2013)... limb is lost as a consequence of diabetic foot ... that can change this situation are very limited. In ... School and the Department of Medical Biochemistry and Biophysics ... wound treatment that may completely change the lives of ... severe type of chronic wounds that largely impair the ...
    (Date:5/20/2013)... 2013 BenefitMall, the leading ... payroll products and services and CompuPay, Inc., ... as finalists for the 2013 American Business Awards. BenefitMall ... Year category, and CompuPay is a finalist for Customer ... be a Gold, Silver or Bronze Stevie® Award Winner ...
    (Date:5/20/2013)... 2013 Soliant Health, a leading specialty healthcare ... voting for its fifth annual Most Beautiful Hospitals in the ... year, Soliant decided to bypass its routine selection process and ... received to be in the running for the 2013 Most ... May 20 and runs through June 23. Winners will be ...
    Breaking Medicine News(10 mins):Health News:Sporturf Expands into the Midwestern U.S. 2Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 2Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 3Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 4Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 5Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 6Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 7Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 8Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 9
    ... In a research study appearing in the journal ... Harbor Laboratory (CSHL) and four other institutions have identified a ... has limited treatment options and one of the worst one-year ... that up to 15% of liver tumors are "driven" by ...
    ... Mutations in three pathways important for suppressing tumors ... that strikes children and adults. But new research ... those changes alone are not sufficient to cause ... different points in the same disrupted regulatory pathways. ...
    ... Spanish . The Hospital Clnic of Barcelona presented today ... Felipe Garcia and Dr. Agata Len , from the Hospital ... Gatell . The tool has been created by a team from the ... and Csar Cceres . Through a direct connection via a webcam, ...
    ... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
    ... the brain transmits messages to other parts of the ... dementia, multiple sclerosis and stroke. Scientists at the ... maintaining the health and function of the segment of ... brain. The study, published in the journal ...
    ... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Stony ... a "wearable," portable PET scanner they,ve developed for rats. ... simultaneously studying brain function and behavior in fully awake, ... validation studies in the April 2011 issue of Nature ...
    Cached Medicine News:Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3Health News:Key mutations act cooperatively to fuel aggressive brain tumor 2Health News:Key mutations act cooperatively to fuel aggressive brain tumor 3Health News:Virtual assistance is confirmed as an effective tool in monitoring HIV patients 2Health News:Virtual assistance is confirmed as an effective tool in monitoring HIV patients 3Health News:Miniature 'wearable' PET scanner ready for use 2Health News:Miniature 'wearable' PET scanner ready for use 3Health News:Miniature 'wearable' PET scanner ready for use 4
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: